Suppr超能文献

评估原发性甲状腺功能减退症孕妇对左甲状腺素的依从性和甲状腺刺激素水平超出范围的情况。

Evaluation of adherence to levothyroxine and out-of-range thyroid-stimulating hormone levels in pregnant women with primary hypothyroidism.

机构信息

Endocrinology Clinics, Kocaeli Derince Training and Research Hospital, University of Health Sciences, Kocaeli, Turkey.

Gynecology and Obstetrics Clinics, Kocaeli Derince Training and Research Hospital, University of Health Sciences, Kocaeli, Turkey.

出版信息

Int J Clin Pract. 2021 Aug;75(8):e14312. doi: 10.1111/ijcp.14312. Epub 2021 May 17.

Abstract

PURPOSE

Adherence to levothyroxine (LT4) and attaining thyroid-stimulating hormone (TSH) goal in pregnancy has not been well-defined yet. We aimed to investigate adherence to LT4, success to reach TSH goal, and association between them in pregnant women with primary hypothyroidism.

MATERIALS AND METHODS

Eight-item Morisky Medication Adherence Scale (MMAS-8) was applied in third trimester in pregnant women with primary hypothyroidism (Hashimoto's thyroiditis, surgical hypothyroidism or iodine deficiency) whom LT4 was given for at least 3 months. Those with chronic illness or thyroid cancer were excluded. We grouped the patients according to MMAS-8 score (<6, low adherence vs ≥6, medium/high adherence), and TSH measurement in third trimester (in-range vs out-of-range).

RESULTS

Of total (n = 85), 57.64% (n = 49) had medium/high adherence to LT4, and 41.17% (n = 35) out-of-range TSH, but no association was found among them (P = .937). LT4 initiation in pregestational period, surgical hypothyroidism, high LT4 dose in second/third trimester and alternate-day dosing were associated with medium/high adherence. Age, number of visits, and less time between ingestion of LT4 and breakfast were associated with medium/high adherence. LT4 dose in second trimester and dose increment at the beginning of pregnancy were positively associated with in-range TSH.

CONCLUSION

Non-adherence and treatment failure are frequent in LT4-treated pregnant women. Adherence seems not to be associated with treatment success. Regular follow-up may improve adherence. Our study is the first to analyse both treatment success and adherence to LT4 in pregnancy.

摘要

目的

左旋甲状腺素(LT4)的依从性和甲状腺刺激激素(TSH)在妊娠期间的达标情况尚未得到很好的定义。我们旨在研究原发性甲状腺功能减退症孕妇 LT4 的依从性、达到 TSH 目标的成功率以及两者之间的相关性。

材料和方法

在原发性甲状腺功能减退症(桥本甲状腺炎、手术性甲状腺功能减退症或碘缺乏症)孕妇的妊娠晚期应用 8 项 Morisky 药物依从性量表(MMAS-8),这些孕妇至少接受了 3 个月的 LT4 治疗。排除患有慢性疾病或甲状腺癌的孕妇。根据 MMAS-8 评分(<6,低依从性与≥6,中/高依从性)和妊娠晚期 TSH 测量值(在范围内与不在范围内)将患者分组。

结果

在总共 85 名患者中,57.64%(n=49)对 LT4 具有中/高依从性,41.17%(n=35)TSH 不在范围内,但两者之间没有相关性(P=0.937)。孕前开始 LT4 治疗、手术性甲状腺功能减退症、妊娠中期/晚期 LT4 剂量较高和隔日给药与中/高依从性相关。年龄、就诊次数以及 LT4 摄入与早餐之间的时间较短与中/高依从性相关。妊娠中期 LT4 剂量和妊娠开始时的剂量增加与 TSH 在范围内呈正相关。

结论

LT4 治疗的孕妇中经常出现不依从和治疗失败。依从性似乎与治疗效果无关。定期随访可能会提高依从性。我们的研究首次分析了妊娠期间 LT4 的治疗效果和依从性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验